Home >> Marketplace Directory >> FDA clears NeuMoDx 288 system, GBS assay

FDA clears NeuMoDx 288 system, GBS assay

image_pdfCreate PDF

September 2018—NeuMoDx Molecular announced it has received FDA 510(k) clearance for its NeuMoDx 288 Molecular System and NeuMoDx GBS Assay. The fully automated NeuMoDx 288 is a scalable platform that integrates the diagnostic process, from extraction to detection, in approximately one hour. The analyzer can load up to 288 patient samples in a continuous random-access mode and features a walkaway time of more than six hours.

The dry format reagents do not require refrigeration and have an onboard stability of more than 60 days and an ambient temperature storage shelf life of more than one year. The unitized format of the dry reagents aims to increase operating efficiency while minimizing the waste associated with systems requiring manual reconstitution or use of bulk format lyophilized reagents.

CAP TODAY
X